KR890003952A - 신규 조직 플라스미노겐 활성제 - Google Patents

신규 조직 플라스미노겐 활성제 Download PDF

Info

Publication number
KR890003952A
KR890003952A KR1019880009836A KR880009836A KR890003952A KR 890003952 A KR890003952 A KR 890003952A KR 1019880009836 A KR1019880009836 A KR 1019880009836A KR 880009836 A KR880009836 A KR 880009836A KR 890003952 A KR890003952 A KR 890003952A
Authority
KR
South Korea
Prior art keywords
plasminogen activator
tissue plasminogen
amino acid
acid sequence
asn
Prior art date
Application number
KR1019880009836A
Other languages
English (en)
Other versions
KR970001237B1 (ko
Inventor
미네오 니와
요시마사 사이또
히도시 사사끼
마사꼬 히야시
조우지 노따니
마사까즈 고바야시
Original Assignee
후지사와 도모끼찌로
후지사와 야꾸힝 고교가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878718298A external-priority patent/GB8718298D0/en
Priority claimed from GB878725052A external-priority patent/GB8725052D0/en
Priority claimed from GB878726683A external-priority patent/GB8726683D0/en
Application filed by 후지사와 도모끼찌로, 후지사와 야꾸힝 고교가부시끼가이샤 filed Critical 후지사와 도모끼찌로
Publication of KR890003952A publication Critical patent/KR890003952A/ko
Application granted granted Critical
Publication of KR970001237B1 publication Critical patent/KR970001237B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

신규 조직 플라스미노겐 활성제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 플라스미드 pHVBB의 구성 및 클로닝(cloning)을 나타낸 것임. 제2도는 플라스미드 pCLiPAxtrp의 구성 및 클로닝을 나타낸 것임. 제3도는 BgI II DNA절편 1974bp의 DNA서열을 나타낸 것임.

Claims (14)

  1. 일차 구조로서 하기 아미노산 서열(Ⅰ)에 의해 표시되는 조직 플라스미노겐 활성제.
    180 190
    R-GluGlyAsnSerAs pCysTyrPheGlyAsnGlySerAlaTyrArgGlyThrHisSerLeuThrGluSerGlyAl
    200 210 220
    aSerCysLeuProTrpAsnSerMetIleLeuIleGlyLysValTyrThrAlaGlnAsnProSerAlaGlnAlaLeu
    230 240 250
    lyLeuGlyLysHisAsnTyrCysArgAsnProAspGlyAspAlaLysPrpTrpCysHisValLeuLysAsnArgAr
    260 270 277
    gLeuThrTrpGluyTyrCysAspValProSerCysSerThrCysGlyLeuArgGln ━━ Y ━━Ile-X-Gly
    280 290 300 GlyLeuPheAlaAspIleAlaSerHisProTrpGlnAlaAlaIlePheAlaLysHisArgArgSerProGlyGluA
    310 320
    rgPheLeuCysGlyGlyIleLeuIleSerSerCysTrpIleLeuSarAlaAlaHisCysPheGlnGluArgPhePro
    330 340 350
    ProHisHisLeuThrValIleLauGlyArgThrTyrArgValValProGluGluGluGluGlnLysPheGluValGl
    360 370 380
    uLysTyrIleValHisLysGluPheAspAspAspThrTyrAspAsnAspIleAlaLeuGlnLeuLysSerAspSerS
    390 400
    erArgCysAlaGlnGluSerSerValValArgThrValCysLeuProProAlaAspLeuGlnLeuProAspTrpThr
    410 420 430
    GluCysGluLeuSerGlyTyrGlyLysHisGluAlaLeuSerProPheTyrSerGluArgLeuLysGluAlaHisV
    440 450
    alArgLeuTyrProSerSerArgCysThrSerGlnHisLeuLeuAsnArgThrValThrAspAsnMetLeuCysAl
    460 470 480
    aGlyAspThrArgSerGlyGlyProGlnAlaAsHisAspAlaCysGlnGlyAspSerGlyGlyPorLeuValCysL
    490 500
    euValCysLeuAsnAspGlyArgMetThrLeuValGlyIleIleSerTrpGlyLeuGlyCysGlyGlnLysAspVa
    510 520 527
    lProGlyValTyrThrLysValThrAsnTyrLeuAspTrpIleArgAspAsnMetArgPro
    92 100 이 서열에서 R은 Ser 또는 CysTyrGluAspGlnGlyIleSerTyrArgGlyThrTrpSerThrAlaGlu
    110 120 130
    SerGlyAlaGluCysThrAsnTrpAsnSerSerAlaLeuAlaGlnLysProTyrSerGlyArgArgProAspAlaI
    140 150
    leArgLeuGlyLeuGlyAsnHisAsnTyrCysArgAsnProAspArgAspSerLysProTrpCysTyrValPheLy
    160 170 174
    sAlaGlyLysTyrSerSerGluPheCysSerThrProAlaCysSer-이고, X는 -Lys- 또는 -Ile- 또는 결합손(bond)이고,Y는-TyrSerGlnProGlnPheArgIle-,-TySerGlnProGlnPheAspIle-, -TyrSerGlnProIlePorArgSer- 또는 -ThrLeuArgProArgPheLysIle이고, Asn181, Asn218및
    Asn448은 글리코실화될 수 있음.
  2. 제1항에 있어서, 그리코실화 되지 않은 조직 플라스미노겐 활성제.
  3. 제1항에 있어서, R은 Ser-이고,X는 -Lys-이고 Y는 TyrserGlnProGlnPheApIle-인 조직 플라스미노겐 활성제.
  4. 제2항에 있어서,R이 Ser-이고,X가 -Lys-이고 Y가 TyrserGlnProGlnPheApIle-인 조직 플라스미노겐 활성제.
  5. 제1항에서 정의된 바와같은 아미노산 서열(Ⅰ)을 암호하는 DNA.
  6. 제1항에서 정의된 바와같은, 아미노산 서열(Ⅰ)을 암호하는 DNA로 되는 재조합 벡터.
  7. 제1항에서 정의된 바와같은, 아미노산 서열(Ⅰ)을 암호하는 DNA서열의 발현벡터로 되는 형질 전환제.
  8. 형질 전환된 숙주세포를 제1항에 정의된 바와같은 아미노산 서열(Ⅰ)을 암호하는 DNA로 되는 발현벡터와 함께 영양 배지중에서 배양시키고, 생성된 t-PA를 배양육즙에서 회수함으로 되는 제1항의 조직 플라스미노겐 활성제의 제조 방법.
  9. 제1항의 조직 플라스미노겐 활성제 및 제약상 허용되는 담체(들)로 되는 제약 조성물.
  10. 본질적으로 기타 인체 및 동물에서 기원된 단백질이 없는, 지시 및 생장요인 영역부재 조직 플라스미노겐 활성제.
  11. 글리코실화 되지 않은, 지시 및 생장요인 영역부재 조직 플라스미노겐 활성제.
  12. 본질적으로 천연 인체 조지기 플라스미노겐 활성제에 대응하는 중사슬의 크링글 2영역 및 경사슬로 구성되고, 본질적으로 기타 인체 및 동물에서 기원한 단백질이 없는 조직 플라스미노겐 활성제.
  13. 글리코실화 되지 않은, 본질적으로 천연 인체 조직 프라스미노겐 활성제에 대응하는 중사슬의 크링글2영역 및 경사슬로 구성된 조직 플라스미노겐 활성제.
  14. 제13항에 있어서, 천연 인체 조직 플라스미노겐 활성제의 275위치의 아르기닌 잔기가 아스파르트산 잔기로 대치된 조직 플라스미노겐 활성제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880009836A 1987-08-03 1988-08-02 신규 조직 플라스미노겐 활성제 KR970001237B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB878718298A GB8718298D0 (en) 1987-08-03 1987-08-03 Tissue plasminogen activator
GB8718298 1987-08-03
GB8725052 1987-10-26
GB878725052A GB8725052D0 (en) 1987-10-26 1987-10-26 Tissue plasminogen activator
GB878726683A GB8726683D0 (en) 1987-11-13 1987-11-13 Tissue plasminogen activator
GB8726683 1987-11-13

Publications (2)

Publication Number Publication Date
KR890003952A true KR890003952A (ko) 1989-04-19
KR970001237B1 KR970001237B1 (ko) 1997-02-04

Family

ID=27263535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880009836A KR970001237B1 (ko) 1987-08-03 1988-08-02 신규 조직 플라스미노겐 활성제

Country Status (11)

Country Link
US (2) US5648250A (ko)
EP (1) EP0302456B1 (ko)
JP (3) JP2561708B2 (ko)
KR (1) KR970001237B1 (ko)
AT (1) ATE108206T1 (ko)
AU (1) AU623340B2 (ko)
CA (1) CA1341458C (ko)
DE (1) DE3850531T2 (ko)
DK (1) DK174413B1 (ko)
ES (1) ES2056082T3 (ko)
IL (1) IL87276A (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it
IL88247A0 (en) * 1987-11-06 1989-06-30 Genentech Inc Novel human tissue-type plasminogen activator variant
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
DE3923339A1 (de) * 1989-05-31 1990-12-06 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator-derivat
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
GB9204439D0 (en) 1992-02-27 1992-04-15 Fujisawa Pharmaceutical Co A new cephalosporin c acylase
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
DE19937219A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6821755B2 (en) * 2000-07-27 2004-11-23 Boehringer Ingelheim International Gmbh Preparation of a recombinant protein in a prokaryotic host cell
GB0027779D0 (en) * 2000-11-14 2000-12-27 Boehringer Ingelheim Int Methods for large scale production of recombinant dna-derived tpa or k2s molecules
US6955910B2 (en) 2000-11-14 2005-10-18 Boehringer Ingelheim International Gmbh Method for large scale production of recombinant DNA-derived TPA or K2S molecules
US7087412B2 (en) 2000-11-14 2006-08-08 Boehringer Ingelheim International Gmbh Methods for large scale protein production in prokaryotes
GB0029001D0 (en) * 2000-11-28 2001-01-10 Isis Innovation Assay
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
KR100855024B1 (ko) 2008-04-30 2008-08-28 가톨릭대학교 산학협력단 크링글 도메인 １ 및 ２ 로 이루어진 비-글리코실화 재조합단백질
EP2289542A1 (en) * 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
EP0125254A1 (en) * 1982-10-28 1984-11-21 Beecham Group Plc Enzyme derivatives and their use in the treatment of thrombosis
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
US4577584A (en) * 1984-12-24 1986-03-25 Shih Nan C Bell lock (II)
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GB8508717D0 (en) * 1985-04-03 1985-05-09 Beecham Group Plc Composition
EP0199574B1 (en) * 1985-04-22 1991-10-23 Genentech, Inc. Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
PT84588B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
US5376547A (en) * 1987-01-30 1994-12-27 American Home Products Corporation Des-epidermal growth factor plasminogen activators
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it

Also Published As

Publication number Publication date
DK174413B1 (da) 2003-02-17
CA1341458C (en) 2004-10-12
AU623340B2 (en) 1992-05-14
US5840533A (en) 1998-11-24
JP2561708B2 (ja) 1996-12-11
DE3850531T2 (de) 1994-11-24
IL87276A (en) 1995-07-31
KR970001237B1 (ko) 1997-02-04
JP2606620B2 (ja) 1997-05-07
AU2036188A (en) 1989-02-09
EP0302456B1 (en) 1994-07-06
JP2570633B2 (ja) 1997-01-08
EP0302456A1 (en) 1989-02-08
JPH08228773A (ja) 1996-09-10
DE3850531D1 (de) 1994-08-11
DK431988D0 (da) 1988-08-02
ATE108206T1 (de) 1994-07-15
JPH07163346A (ja) 1995-06-27
ES2056082T3 (es) 1994-10-01
IL87276A0 (en) 1988-12-30
JPH01104167A (ja) 1989-04-21
US5648250A (en) 1997-07-15
DK431988A (da) 1989-02-04

Similar Documents

Publication Publication Date Title
KR890003952A (ko) 신규 조직 플라스미노겐 활성제
KR880010130A (ko) 폴리 펩티드, dna 및 그의 용도
KR870002264A (ko) 폴리-크링글 플라스미노겐 활성화제의 제조방법
ES8505405A1 (es) Un procedimiento para producir un activador de plasminogeno purificado.
HUP0101136A2 (hu) Fehérjeexpresszió baculovírus-vektort alkalmazó expressziós rendszerben
ATE74379T1 (de) Peptidplasminogenaktivatoren.
KR890000103A (ko) 조직 플라스미노겐 활성화제(t-PA) 활성을 갖는 단백질의 고농도 용액의 제조방법, t-PA 활성을 갖는 단백질을 함유하는 용액, 및 인체 및 수의약제에 있어서 용액의 용도
WO1991018989A1 (en) Hybrid plasminogen activator mutants
EP0219270A3 (en) Method of enhancing tissue plasminogen activator and single chain urokinase plasminogen activator production
ES2043610T3 (es) Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
SE8702562L (sv) Nya fibrinolytiska enzymer
EP0241210B1 (en) Modified enzyme
ATE102994T1 (de) Verfahren zur herstellung von proteinen.
DK0387646T3 (da) Achromobacter-protease I-gen og genprodukt deraf
ES8602117A1 (es) Un procedimiento para producir un uroquinasa-zimogeno
KR890701733A (ko) 신규 인체 조직형 플리스미노겐 활성제 변이체
DE69022233D1 (de) Protein mit transaktivierender eigenschaft, dieses protein exprimierende vektoren, zellinien und seine verwendungen.
EP0292326A2 (en) Modified enzyme
FI902066A0 (fi) Nya polypeptidfoereningar.
Petri et al. Novel plasminogen activators from the vampire bat Desmodus rotundus
Rabiet et al. Molecular defect in prothrombin Madrid: Substitution of arginine 273 by cysteine precludes activation
Dodd et al. Effect of harvest medium composition on yield and chain nature of recombinant tissue-type plasminogen activator species
EP0227102A2 (en) Cell line established from human normal uterine muscle, method for producing plasminogen activator using the cell line, and plasminogen activator
DE69105213D1 (de) Substitutionsvariante des gewebeplasminogenaktivators.
Church et al. A SHARED EPITOPE ON HUMAN PROTEIN C, FACTOR X, FACTOR VII, AND PROTTOBIN DEFINED BY A MONOCLONAL ANTIBODY

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110126

Year of fee payment: 15

EXPY Expiration of term